JMP notes despite the incredible clinical and commercial success of Merck & Co. Inc’s (NYSE:MRK) Keytruda (pembrolizumab) and Bristol Myers Squibb & Co’s (NYSE:BMY) Opdivo (nivolumab ...
JMP Securities initiates coverage on Summit Therapeutics, citing promising data for ivonescimab in NSCLC and setting a $32 ...
JMP notes despite the incredible clinical and commercial success of Merck & Co. Inc’s (NYSE:MRK) Keytruda (pembrolizumab) and Bristol Myers Squibb & Co’s (NYSE:BMY) Opdivo (nivolumab), ivonescimab ...
Opdivo and Yervoy improve cure rates in resected stage 3/4 melanoma compared to placebo, with Opdivo showing superior efficacy. CheckMate 238 and EORTC 18071 trials reveal Opdivo's cure rate advantage ...
Overall, the results with Keytruda are very similar to that seen with BMS’ PD-1 inhibitor Opdivo (nivolumab), which was approved by the FDA for the same HCC indication in September 2017.
The clinical trial for the Cabometyx-Opdivo therapy showed reduced efficacy compared with Keytruda-Inlyta. The objective response rate was 55.7% for the combination therapy compared with 27% for ...
The increase came from Eliquis and the company's so-called Growth Portfolio of drugs, which includes a cancer drug called Opdivo. But revenue was partially offset by leukemia treatment Sprycel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback